Exjade receives positive opinion from EMA
Novartis' Exjade has received positive opinion from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Exjade is used to treat chronic iron overload requiring chelation therapy when deferoxamine therapy is insufficient in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT) syndromes.
According to the company, Exjade would be the first oral treatment in the European Union, to treat iron overload in patients with the mentioned types of thalassemia.
Novartis Oncology president Hervé Hoppenot said patients with NTDT have suffered the effects of iron overload without accurate diagnosis, clear treatment guidelines or approved oral therapies.
"The CHMP recommendation is an important step toward improving the outcomes of patients with this type of thalassemiam," Hoppenot added.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250